Next-Generation Sequencing Reveals a High Frequency of HIV-1 Minority Variants and an Expanded Drug Resistance Profile Among Individuals on First-Line ART

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2024 Sep 28

PMID 39339930

Authors

Maria Nannyonjo

Jonah Omooja

Daniel Lule Bugembe

Nicholas Bbosa

Sandra Lunkuse

Stella Esther Nabirye

Faridah Nassolo

Hamidah Namagembe

Andrew Abaasa

Anne Kazibwe

Pontiano Kaleebu

Deogratius Ssemwanga

Affiliations

Soon will be listed here.

Abstract

We assessed the performance and clinical relevance of Illumina MiSeq next-generation sequencing (NGS) for HIV-1 genotyping compared with Sanger sequencing (SS). We analyzed 167 participants, 45 with virologic failure (VL ≥ 1000 copies/mL), i.e., cases, and 122 time-matched participants with virologic suppression (VL < 1000 copies/mL), i.e., controls, 12 months post-ART initiation. Major surveillance drug resistance mutations (SDRMs) detected by SS were all detectable by NGS. Among cases at 12 months, SS identified SDRMs in 32/45 (71.1%) while NGS identified SDRMs among 35/45 (77.8%), increasing the number of cases with SDRMs by 3/45 (6.7%). Participants identified with, and proportions of major SDRMs increased when NGS was used. NGS vs. SS at endpoint revealed for NNRTIs: 36/45 vs. 33/45; Y181C: 26/45 vs. 24/45; K103N: 9/45 vs. 6/45 participants with SDRMs, respectively. At baseline, NGS revealed major SDRMs in 9/45 (20%) cases without SDRMs by SS. Participant MBL/043, among the nine, the following major SDRMs existed: L90M to PIs, K65R and M184V to NRTIs, and Y181C and K103N to NNRTIs. The SDRMs among the nine increased SDRMs to NRTIs, NNRTIs, and PIs. Only 43/122 (25.7%) of participants had pre-treatment minority SDRMs. Also, 24.4% of the cases vs. 26.2 of controls had minority SDRMs ( = 0.802); minority SDRMs were not associated with virologic failure. NGS agreed with SS in HIV-1 genotyping but detected additional major SDRMs and identified more participants harboring major SDRMs, expanding the HIV DRM profile of this cohort. NGS could improve HIV genotyping to guide treatment decisions for enhancing ART efficacy, a cardinal pre-requisite in the pursuit of the UNAIDS 95-95-95 targets.

References

Tzou P, Ariyaratne P, Varghese V, Lee C, Rakhmanaliev E, Villy C . Comparison of an Diagnostic Next-Generation Sequencing Assay with Sanger Sequencing for HIV-1 Genotypic Resistance Testing. J Clin Microbiol. 2018; 56(6). PMC: 5971553. DOI: 10.1128/JCM.00105-18. View

Hoffmann C, Minkah N, Leipzig J, Wang G, Arens M, Tebas P . DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res. 2007; 35(13):e91. PMC: 1934997. DOI: 10.1093/nar/gkm435. View

Dudley D, Chin E, Bimber B, Sanabani S, Tarosso L, Costa P . Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One. 2012; 7(5):e36494. PMC: 3344889. DOI: 10.1371/journal.pone.0036494. View

Chen Q, Perales C, Soria M, Garcia-Cehic D, Gregori J, Rodriguez-Frias F . Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Res. 2019; 174:104694. DOI: 10.1016/j.antiviral.2019.104694. View

Varghese V, Shahriar R, Rhee S, Liu T, Simen B, Egholm M . Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2009; 52(3):309-15. PMC: 2809083. DOI: 10.1097/QAI.0b013e3181bca669. View

Quinones-Mateu M, Arts E . Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat. 2003; 5(6):224-33. DOI: 10.1016/s1368-7646(02)00123-1. View

Hwang J, Ahn S, Kwon M, Seo J, Hwang S, Jee B . Whole-genome next-generation sequencing and phylogenetic characterization of viral haemorrhagic septicaemia virus in Korea. J Fish Dis. 2020; 43(5):599-607. DOI: 10.1111/jfd.13150. View

Boltz V, Zheng Y, Lockman S, Hong F, Halvas E, McIntyre J . Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A. 2011; 108(22):9202-7. PMC: 3107269. DOI: 10.1073/pnas.1105688108. View

Segujja F, Omooja J, Lunkuse S, Nanyonjo M, Nabirye S, Nassolo F . High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda. AIDS Res Hum Retroviruses. 2020; 36(9):782-791. DOI: 10.1089/AID.2019.0279. View

10.

Taylor T, Lee E, Nykoluk M, Enns E, Liang B, Capina R . A MiSeq-HyDRA platform for enhanced HIV drug resistance genotyping and surveillance. Sci Rep. 2019; 9(1):8970. PMC: 6586679. DOI: 10.1038/s41598-019-45328-3. View

11.

Metzner K, Giulieri S, Knoepfel S, Rauch P, Burgisser P, Yerly S . Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis. 2008; 48(2):239-47. DOI: 10.1086/595703. View

12.

Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J . Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PLoS One. 2010; 5(6):e10952. PMC: 2880604. DOI: 10.1371/journal.pone.0010952. View

13.

Kityo C, Boerma R, Sigaloff K, Kaudha E, Calis J, Musiime V . Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children. J Antimicrob Chemother. 2017; 72(9):2587-2595. PMC: 5890670. DOI: 10.1093/jac/dkx188. View

14.

Kaleebu P, Kirungi W, Watera C, Asio J, Lyagoba F, Lutalo T . Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda. PLoS One. 2015; 10(12):e0145536. PMC: 4689474. DOI: 10.1371/journal.pone.0145536. View

15.

Codoner F, Pou C, Thielen A, Garcia F, Delgado R, Dalmau D . Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PLoS One. 2011; 6(5):e19461. PMC: 3094345. DOI: 10.1371/journal.pone.0019461. View

16.

Arias A, Lopez P, Sanchez R, Yamamura Y, Rivera-Amill V . Sanger and Next Generation Sequencing Approaches to Evaluate HIV-1 Virus in Blood Compartments. Int J Environ Res Public Health. 2018; 15(8). PMC: 6122037. DOI: 10.3390/ijerph15081697. View

17.

Silver N, Paynter M, McAllister G, Atchley M, Sayir C, Short J . Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther. 2018; 15(1):18. PMC: 6223033. DOI: 10.1186/s12981-018-0206-y. View

18.

Santiago-Rodriguez T, Hollister E . Human Virome and Disease: High-Throughput Sequencing for Virus Discovery, Identification of Phage-Bacteria Dysbiosis and Development of Therapeutic Approaches with Emphasis on the Human Gut. Viruses. 2019; 11(7). PMC: 6669467. DOI: 10.3390/v11070656. View

19.

Zagordi O, Klein R, Daumer M, Beerenwinkel N . Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Res. 2010; 38(21):7400-9. PMC: 2995073. DOI: 10.1093/nar/gkq655. View

20.

Ayitewala A, Ssewanyana I, Kiyaga C . Next generation sequencing based in-house HIV genotyping method: validation report. AIDS Res Ther. 2021; 18(1):64. PMC: 8487565. DOI: 10.1186/s12981-021-00390-8. View